Dachaigh › Ailseachadh an Ae (Carcinoma Hepatocellular) › New York › New York City
Sgrùdaidhean clionaigeach Ailseachadh an Ae (Carcinoma Hepatocellular) ann an New York City, NY
Tha 24 sgrùdaidhean airson Ailseachadh an Ae (Carcinoma Hepatocellular) a’ lorg phàirtichean aig làraichean ann agus timcheall air New York City (taobh a-staigh mu 30 mìle). Fosglaidh sgrùdadh gus faicinn cò as urrainn pàirt a ghabhail agus mar a chuireas tu fios air an sgioba.
Teacsa sgrùdaidh oifigeil (Beurla)
A’ fastadh airson sgrùdadh an seo? Seall e aig mullach na duilleige seo — $99 airson 30 latha →
A Study of ZW251 in Participants With Advanced Solid Tumors
A’ fastadhÌre 1
- Memorial Sloan Kettering Cancer Center, New York
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
A’ fastadhÌre 1
- Exelixis Clinical Site #60, New York
- Exelixis Clinical Site #6, New York
Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC
A’ fastadhÌre 1/2
- Research Facility, New York
Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
A’ fastadhÌre 1
- Columbia University Irving Medical Center, New York
A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
A’ fastadhÌre 1/2
- Memorial Sloan Kettering Cancer Center Mskcc, New York
Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)
A’ fastadhSgrùdadh amharc
- NYU Langone Health, New York
- Columbia University Irving Medical Center, New York
- Memorial Sloan Kettering Cancer Center, New York
- agus 1 a bharrachd
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
A’ fastadhÌre 3
- Research Site, New York
- Research Site, New York
- Research Site, New York
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
A’ fastadhÌre 1
- New York Cancer & Blood Specialists, New York
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
A’ fastadhÌre 1/2
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
FOG-001 in Locally Advanced or Metastatic Solid Tumors
A’ fastadhÌre 1/2
- Memorial Sloan Kettering Cancer Center, New York
Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
A’ fastadhÌre 3
- Mount Sinai Hospital, New York
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
A’ fastadhÌre 1/2
- NYU Langone Health, New York
- Icahn School of Medicine At Mount Sinai Prime, New York
Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant
A’ fastadhÌre 4
- Icahn School of Medicine at Mount Sinai, New York
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
A’ fastadhÌre 2
- Columbia University Irving Medical Center, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
A’ fastadhÌre 1
- Clinical Trial Site, New York
Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI
A’ fastadh
- VA NY Harbor Healthcare System, New York, NY, New York
A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
A’ fastadhÌre 1
- Memorial Sloan Kettering Cancer Center, New York
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
A’ fastadhÌre 2
- USA04-0, New York
A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
A’ fastadhÌre 1/2
- Memorial Sloan Kettering Cancer Center - New York, New York
HOPE Against Cancer Recurrence in HCC
A’ fastadhÌre 4
- Rutgers New Jersey Medical School (New York), New York
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
A’ fastadhÌre 1/2
- Research Site 107, New York
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
A’ fastadhSgrùdadh amharc
- Massive Bio SYNERGY-AI site, New York
The Dragon PLC Trial (DRAGON-PLC)
A’ fastadh
- Memorial Sloan Kettering Cancer Center, New York
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
A’ fastadhÌre 1/2
- Memorial Sloan-Kettering Cancer Center, New York
Sgrùdaidhean Ailseachadh an Ae (Carcinoma Hepatocellular) ann am bailtean eile
- Houston, TX31 sgrùdaidhean
- Dallas, TX19 sgrùdaidhean
- Los Angeles, CA19 sgrùdaidhean
- Boston, MA18 sgrùdaidhean
- Cleveland, OH18 sgrùdaidhean
- Chicago, IL16 sgrùdaidhean
- Philadelphia, PA16 sgrùdaidhean
- Pittsburgh, PA15 sgrùdaidhean
- San Francisco, CA14 sgrùdaidhean
- Orange, CA14 sgrùdaidhean
- Jacksonville, FL14 sgrùdaidhean
- San Antonio, TX13 sgrùdaidhean
Sgrùdaidhean eile ann an New York City
- Aillse a' bhroilleach136 sgrùdaidhean
- Aillse Sgamhain Neo-chealla-beag121 sgrùdaidhean
- Aillse (gach seòrsa)109 sgrùdaidhean
- Aillse Prostata103 sgrùdaidhean
- Ailse metastatach93 sgrùdaidhean
- Aillse colorectal78 sgrùdaidhean
- Cancer Ovarian69 sgrùdaidhean
- Ailseachadh nan Sgamhan60 sgrùdaidhean
- Myeloma iomaill60 sgrùdaidhean
- Cancer Pancreatic60 sgrùdaidhean
- Ailse Endometrial52 sgrùdaidhean
- Leukemia myeloid geur51 sgrùdaidhean
Bho ClinicalTrials.gov, dàta air a thogail 6 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.